Biologic and Chemical Medicines – Differences in Terms of Basic Scientific and Regulatory Aspects


Biological Medicine
Chemical Medicine
Generic Medicines
Regulatory Environment
Monoclonal Antibodies

How to Cite

Ganugrava, N., & Megrelishvili, M. (2024). Biologic and Chemical Medicines – Differences in Terms of Basic Scientific and Regulatory Aspects. Georgian Scientists, 6(1), 58–67.


Biological Medicines represent an innovative advance in Healthcare, offering targeted and immunotherapies for a wide range of complex diseases. In this scientific article, we aim to present the fundamental differences between biological and chemical medicines in terms of mechanism of action, manufacturing process and regulatory environment. Additionally, we will discuss the basic scientific aspects of biosimilar and generic medicines, focusing on their regulatory details, which have a significant impact on patients care and healthcare system


EMA. Biological Medicines Accessed December. 2023

FDA. Biological Product Definitions Accessed December, 2023

Manufacturing Process of Biologics Accessed December, 2023

Arnold G. Vulto, Orlando A. Jaquez - The process defines the product: what really matters in biosimilar design and production? Rheumatology 2017;56:iv14iv29


EMA. Generic and Hybrid Medicines Accessed December, 2023

FDA. Generic Drugs Accessed December, 2023

FDA. Biosimilars. Accessed December, 2023

Guidelines on evaluation of similar biotherapeutic products (SBPs). In: WHO Expert Committee on Biological Standardization: Sixtieth report. Geneva: World Health Organization; 2013: Annex 2 (WHO Technical Report Series, No. 977;, accessed December 2023).

EMA. Biosimilars overview. Accessed December 2023

EMA. Similar biological medicinal products- Scientific guideline Accessed December, 2023

EMA. Biosimilars in EU. Accessed December, 2023

ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products – Scientific guideline Accessed December, 2023

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B. 1999 guideline recommended for adoption Accessed December 2023

EMA. Immunogenicity assessment of biotechnology-derived therapeutic proteins – Scientific guideline. Accessed December, 2023

WHO. Monoclonal Antibodies (mABs) Accessed December, 2023

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Georgian Scientists


Download data is not yet available.


Metrics Loading ...